» Articles » PMID: 22903130

Endothelin-converting Enzymes and Related Metalloproteases in Alzheimer's Disease

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2012 Aug 21
PMID 22903130
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The efficient clearance of amyloid-β (Aβ) is essential to modulate levels of the peptide in the brain and to prevent it from accumulating in senile plaques, a hallmark of Alzheimer's disease (AD) pathology.We and others have shown that failure in Aβ catabolism can produce elevations in Aβ concentration similar to those observed in familial forms of AD. Based on the available evidence, it remains plausible that in late-onset AD, disturbances in the activity of Aβ degrading enzymes could induce Aβ accumulation, and that this increase could result in AD pathology. The following review presents a historical perspective of the parallel discovery of three vasopeptidases (neprilysin and endothelin-converting enzymes-1 and -2) as important Aβ degrading enzymes. The recognition of the role of these vasopeptidases in Aβ degradation, beyond bringing to light a possible explanation of how cardiovascular risk factors may influence AD risk, highlights a possible risk of the use of inhibitors of these enzymes for other clinical indications such as hypertension. We will discuss in detail the experiments conducted to assess the impact of vasopeptidase deficiency (through pharmacological inhibition or genetic mutation) on Aβ accumulation, as well as the cooperative effect of multiple Aβ degrading enzymes to regulate the concentration of the peptide at multiple sites, both intracellular and extracellular, throughout the brain.

Citing Articles

Cell-specific transcriptional signatures of vascular cells in Alzheimer's disease: perspectives, pathways, and therapeutic directions.

Chaudhuri S, Cho M, Stumpff J, Bice P, Is O, Ertekin-Taner N Mol Neurodegener. 2025; 20(1):12.

PMID: 39876020 PMC: 11776188. DOI: 10.1186/s13024-025-00798-0.


Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.

Faraji P, Kuhn H, Ahmadian S J Mol Neurosci. 2024; 74(3):62.

PMID: 38958788 PMC: 11222241. DOI: 10.1007/s12031-024-02224-4.


Gliovascular transcriptional perturbations in Alzheimer's disease reveal molecular mechanisms of blood brain barrier dysfunction.

Is O, Wang X, Reddy J, Min Y, Yilmaz E, Bhattarai P Nat Commun. 2024; 15(1):4758.

PMID: 38902234 PMC: 11190273. DOI: 10.1038/s41467-024-48926-6.


The Tetraspanin Tspan8 Associates with Endothelin Converting Enzyme ECE1 and Regulates Its Activity.

Zhu Y, Saint-Pol J, Nguyen V, Rubinstein E, Boucheix C, Greco C Cancers (Basel). 2023; 15(19).

PMID: 37835445 PMC: 10571763. DOI: 10.3390/cancers15194751.


Brain Hydrophobic Peptides Antagonists of Neurotoxic Amyloid β Peptide Monomers/Oligomers-Protein Interactions.

Gutierrez-Merino C Int J Mol Sci. 2023; 24(18).

PMID: 37762148 PMC: 10531495. DOI: 10.3390/ijms241813846.


References
1.
Palmer J, Baig S, Kehoe P, Love S . Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol. 2009; 175(1):262-70. PMC: 2708812. DOI: 10.2353/ajpath.2009.081054. View

2.
Iwata N, Tsubuki S, Takaki Y, SHIROTANI K, Lu B, Gerard N . Metabolic regulation of brain Abeta by neprilysin. Science. 2001; 292(5521):1550-2. DOI: 10.1126/science.1059946. View

3.
Mann D . Alzheimer's disease and Down's syndrome. Histopathology. 1988; 13(2):125-37. DOI: 10.1111/j.1365-2559.1988.tb02018.x. View

4.
Cattaruzza F, Cottrell G, Vaksman N, Bunnett N . Endothelin-converting enzyme 1 promotes re-sensitization of neurokinin 1 receptor-dependent neurogenic inflammation. Br J Pharmacol. 2009; 156(5):730-9. PMC: 2697762. DOI: 10.1111/j.1476-5381.2008.00039.x. View

5.
Hafez D, Huang J, Huynh A, Valtierra S, Rockenstein E, Bruno A . Neprilysin-2 is an important β-amyloid degrading enzyme. Am J Pathol. 2011; 178(1):306-12. PMC: 3069828. DOI: 10.1016/j.ajpath.2010.11.012. View